{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T21:05:20Z","timestamp":1790283920347,"version":"4.1.0"},"reference-count":97,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"vor","delay-in-days":10,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000738","name":"US Department of Veterans Affairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedical Journal"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.bj.2026.101038","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T15:05:46Z","timestamp":1789398346000},"page":"101038","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Incretin Revolution: Integrating Incretin-Based Therapies into Clinical Care"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9771-1332","authenticated-orcid":false,"given":"Brian S.","family":"Wojeck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon","family":"Nokes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bj.2026.101038_bib1","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1331\/154434506775268698","article-title":"Exenatide: from the Gila monster to the pharmacy","volume":"46","author":"Triplitt","year":"2006","journal-title":"J Am Pharm Assoc (2003)"},{"issue":"19","key":"10.1016\/j.bj.2026.101038_bib2","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.bj.2026.101038_bib3","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"New England Journal of Medicine"},{"issue":"12","key":"10.1016\/j.bj.2026.101038_bib4","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis","volume":"384","author":"Newsome","year":"2020","journal-title":"New England Journal of Medicine"},{"issue":"24","key":"10.1016\/j.bj.2026.101038_bib5","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bj.2026.101038_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2024.107516","article-title":"Tirzepatide for the treatment of obstructive sleep apnea: Rationale, design, and sample baseline characteristics of the SURMOUNT -OSA phase 3 trial","volume":"141","author":"Malhotra","year":"2024","journal-title":"Contemp Clin Trials"},{"issue":"1","key":"10.1016\/j.bj.2026.101038_bib7","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","article-title":"Glucagon-like peptide-1 receptor: mechanisms and advances in therapy","volume":"9","author":"Zheng","year":"2024","journal-title":"Signal Transduction and Targeted Therapy"},{"key":"10.1016\/j.bj.2026.101038_bib8","doi-asserted-by":"crossref","DOI":"10.1038\/s42255-026-01534-8","article-title":"Semaglutide drives weight loss through cAMP-dependent mechanisms in GLP1R-expressing hindbrain neurons","author":"Gao","year":"2026","journal-title":"Nature Metabolism"},{"issue":"3","key":"10.1016\/j.bj.2026.101038_bib9","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1042\/BST20221066","article-title":"Insulin signalling and GLUT4 trafficking in insulin resistance","volume":"51","author":"van Gerwen","year":"2023","journal-title":"Biochem Soc Trans"},{"issue":"5","key":"10.1016\/j.bj.2026.101038_bib10","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.cmet.2024.04.006","article-title":"Hepatic selective insulin resistance at the intersection of insulin signaling and metabolic dysfunction-associated steatotic liver disease","volume":"36","author":"Bo","year":"2024","journal-title":"Cell Metabolism"},{"issue":"19","key":"10.1016\/j.bj.2026.101038_bib11","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aed0535","article-title":"Integrated analysis of insulin resistance reveals metabolic remodeling following diet switch-triggered calorie reduction","volume":"12","author":"Duan","year":"2026","journal-title":"Sci Adv"},{"key":"10.1016\/j.bj.2026.101038_bib12","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/106237","article-title":"Effect of Bariatric Weight Loss on the Adipose Lipolytic Transcriptome in Obese Humans","volume":"2015","author":"Karki","year":"2015","journal-title":"Mediators Inflamm"},{"issue":"12","key":"10.1016\/j.bj.2026.101038_bib13","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgaa673","article-title":"Weight Loss and Serum Lipids in Overweight and Obese Adults: A Systematic Review and Meta-Analysis","volume":"105","author":"Hasan","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.bj.2026.101038_bib14","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.2337\/db11-1824","article-title":"Protective effects of GLP-1 on glomerular endothelium and its inhibition by PKCbeta activation in diabetes","volume":"61","author":"Mima","year":"2012","journal-title":"Diabetes"},{"issue":"1","key":"10.1016\/j.bj.2026.101038_bib15","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1186\/s12933-022-01585-7","article-title":"Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials","volume":"21","author":"Mosenzon","year":"2022","journal-title":"Cardiovasc Diabetol"},{"issue":"12","key":"10.1016\/j.bj.2026.101038_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhepr.2024.101185","article-title":"Lipid metabolism in MASLD and MASH: From mechanism to the clinic","volume":"6","author":"Carli","year":"2024","journal-title":"JHEP Reports"},{"issue":"4","key":"10.1016\/j.bj.2026.101038_bib17","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.bj.2026.101038_bib18","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes","volume":"377","author":"Holman","year":"2017","journal-title":"N Engl J Med"},{"issue":"10193","key":"10.1016\/j.bj.2026.101038_bib19","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.bj.2026.101038_bib20","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.bj.2026.101038_bib21","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa2501006","article-title":"Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes","volume":"392","author":"McGuire","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bj.2026.101038_bib22","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2026.1764664","article-title":"Tirzepatide vs. semaglutide for obesity, glycemic control, and cardiovascular outcomes: a narrative review of clinical trials","volume":"13","author":"Harbi","year":"2026","journal-title":"Front Med"},{"issue":"24","key":"10.1016\/j.bj.2026.101038_bib23","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1056\/NEJMoa2505928","article-title":"Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes","volume":"393","author":"Nicholls","year":"2025","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.bj.2026.101038_bib24","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1111\/dom.70436","article-title":"Semaglutide and tirzepatide effects on cardiovascular outcomes in people with overweight or obesity in the real world (STEER)","volume":"28","author":"Wilson","year":"2026","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"10.1016\/j.bj.2026.101038_bib25","doi-asserted-by":"crossref","first-page":"808","DOI":"10.2337\/dc25-3063","article-title":"Comparative Effectiveness of Tirzepatide Versus Dulaglutide or Semaglutide on Major Cardiovascular Events in Type 2 Diabetes and Cardiovascular Disease: Insights From Two Target-Trial Emulations","volume":"49","author":"Ostrominski","year":"2026","journal-title":"Diabetes Care"},{"issue":"10489","key":"10.1016\/j.bj.2026.101038_bib26","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1016\/S0140-6736(25)00509-4","article-title":"Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial","volume":"405","author":"Bonaca","year":"2025","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.bj.2026.101038_bib27","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.bj.2026.101038_bib28","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa2410027","article-title":"Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity","volume":"392","author":"Packer","year":"2025","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.bj.2026.101038_bib29","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1001\/jama.2016.10260","article-title":"Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial","volume":"316","author":"Margulies","year":"2016","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.bj.2026.101038_bib30","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/S2213-8587(22)00243-1","article-title":"Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial","volume":"10","author":"Heerspink","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"10.1016\/j.bj.2026.101038_bib31","doi-asserted-by":"crossref","first-page":"430","DOI":"10.2337\/dc24-1773","article-title":"Tirzepatide Associated With Reduced Albuminuria in Participants With Type 2 Diabetes: Pooled Post Hoc Analysis From the Randomized Active- and Placebo-Controlled SURPASS-1-5 Clinical Trials","volume":"48","author":"Apperloo","year":"2025","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.bj.2026.101038_bib32","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1111\/dom.15410","article-title":"Effect of tirzepatide on albuminuria levels and renal function in patients with type 2 diabetes mellitus: A systematic review and multilevel meta-analysis","volume":"26","author":"Karakasis","year":"2024","journal-title":"Diabetes Obes Metab"},{"issue":"5S","key":"10.1016\/j.bj.2026.101038_bib33","first-page":"S1","article-title":"Kidney Disease: Improving Global Outcomes Diabetes Work G. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease","volume":"102","year":"2022","journal-title":"Kidney Int"},{"issue":"5","key":"10.1016\/j.bj.2026.101038_bib34","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.kint.2022.08.012","article-title":"Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO)","volume":"102","author":"de Boer","year":"2022","journal-title":"Kidney Int"},{"key":"10.1016\/j.bj.2026.101038_bib35","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/1379274","article-title":"Incretin-Based Therapy for Prevention of Diabetic Vascular Complications","volume":"2016","author":"Mima","year":"2016","journal-title":"J Diabetes Res"},{"issue":"8","key":"10.1016\/j.bj.2026.101038_bib36","doi-asserted-by":"crossref","first-page":"3488","DOI":"10.1007\/s12325-022-02223-0","article-title":"A Narrative Review of Diabetic Kidney Disease: Previous and Current Evidence-Based Therapeutic Approaches","volume":"39","author":"Mima","year":"2022","journal-title":"Adv Ther"},{"key":"10.1016\/j.bj.2026.101038_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115032","article-title":"Current findings on the efficacy of incretin-based drugs for diabetic kidney disease: A narrative review","volume":"165","author":"Mima","year":"2023","journal-title":"Biomed Pharmacother"},{"issue":"7","key":"10.1016\/j.bj.2026.101038_bib38","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1080\/1744666X.2025.2521086","article-title":"Update on the pathophysiology and treatment of diabetic kidney disease: a narrative review","volume":"21","author":"Mima","year":"2025","journal-title":"Expert Rev Clin Immunol"},{"issue":"6","key":"10.1016\/j.bj.2026.101038_bib39","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.bj.2026.101038_bib40","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 Trial of Semaglutide in Metabolic Dysfunction\u2013Associated Steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bj.2026.101038_bib41","article-title":"Semaglutide Therapy for Metabolic Dysfunction-Associated Steatohepatitis: November 2025 Updates to AASLD Practice Guidance","author":"Bansal","year":"2025","journal-title":"Hepatology"},{"issue":"Supplement_1","key":"10.1016\/j.bj.2026.101038_bib42","doi-asserted-by":"crossref","first-page":"S183","DOI":"10.2337\/dc26-S009","article-title":"Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2026","volume":"49","year":"2026","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1016\/j.bj.2026.101038_bib43","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.2337\/dc21-1785","article-title":"Changes in Glucose Metabolism and Glycemic Status With Once-Weekly Subcutaneous Semaglutide 2.4 mg Among Participants With Prediabetes in the STEP Program","volume":"45","author":"Perreault","year":"2022","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1016\/j.bj.2026.101038_bib44","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S2213-8587(24)00182-7","article-title":"Efficacy and safety of once-weekly semaglutide 2.4 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial","volume":"12","author":"McGowan","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10","key":"10.1016\/j.bj.2026.101038_bib45","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1056\/NEJMoa2410819","article-title":"Tirzepatide for Obesity Treatment and Diabetes Prevention","volume":"392","author":"Jastreboff","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bj.2026.101038_bib46","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.sleep.2024.06.014","article-title":"Weight reduction and the impact on apnea-hypopnea index: A systematic meta-analysis","volume":"121","author":"Malhotra","year":"2024","journal-title":"Sleep Med"},{"issue":"6","key":"10.1016\/j.bj.2026.101038_bib47","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1152\/japplphysiol.00925.2023","article-title":"Effect of obesity on sleep apnea pathogenesis differs in women versus men: multiple mediation analyses in the retrospective SNOOzzzE cohort","volume":"136","author":"Nokes","year":"2024","journal-title":"J Appl Physiol"},{"issue":"5","key":"10.1016\/j.bj.2026.101038_bib48","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1513\/AnnalsATS.202407-752OC","article-title":"Endotypic Traits Characterizing Obesity and Sleep-related Hypoventilation in Patients with Obstructive Sleep Apnea","volume":"22","author":"Hang","year":"2025","journal-title":"Ann Am Thorac Soc"},{"issue":"13","key":"10.1016\/j.bj.2026.101038_bib49","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1056\/NEJMoa2404881","article-title":"Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity","volume":"391","author":"Malhotra","year":"2024","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.bj.2026.101038_bib50","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1038\/s41591-025-04071-1","article-title":"Tirzepatide on obstructive sleep apnea-related cardiometabolic risk: secondary outcomes of the SURMOUNT-OSA randomized trial","volume":"32","author":"Malhotra","year":"2026","journal-title":"Nat Med"},{"issue":"0","key":"10.1016\/j.bj.2026.101038_bib51","article-title":"AHA\/ACC\/ADA\/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"0","author":"Members","year":"2026","journal-title":"Circulation"},{"key":"10.1016\/j.bj.2026.101038_bib52","author":"Khan","year":"2026","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.bj.2026.101038_bib53","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1111\/dom.16176","article-title":"Gastrointestinal tolerability and weight reduction associated with tirzepatide in adults with obesity or overweight with and without type 2 diabetes in the SURMOUNT-1 to -4 trials","volume":"27","author":"Rubino","year":"2025","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"10.1016\/j.bj.2026.101038_bib54","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/dom.14551","article-title":"Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss","volume":"24","author":"Wharton","year":"2022","journal-title":"Diabetes Obes Metab"},{"issue":"Suppl 3","key":"10.1016\/j.bj.2026.101038_bib55","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/dom.14500","article-title":"Understanding the place for GLP-1RA therapy: Translating guidelines for treatment of type 2 diabetes into everyday clinical practice and patient selection","volume":"23","author":"Andreasen","year":"2021","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"10.1016\/j.bj.2026.101038_bib56","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1053\/j.gastro.2025.06.003","article-title":"Glucagon-Like Peptide-1 Receptor Agonists and Gastrointestinal Adverse Events: A Systematic Review and Meta-Analysis","volume":"169","author":"Chiang","year":"2025","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.bj.2026.101038_bib57","doi-asserted-by":"crossref","first-page":"131","DOI":"10.21037\/atm.2018.02.24","article-title":"Incretin-based therapy and pancreatitis: accumulating evidence and unresolved questions","volume":"6","author":"Saisho","year":"2018","journal-title":"Ann Transl Med"},{"issue":"4","key":"10.1016\/j.bj.2026.101038_bib58","doi-asserted-by":"crossref","DOI":"10.1172\/JCI194740","article-title":"The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications","volume":"136","author":"Jalleh","year":"2026","journal-title":"J Clin Invest"},{"issue":"8","key":"10.1016\/j.bj.2026.101038_bib59","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1001\/jamaophthalmol.2024.2296","article-title":"Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide","volume":"142","author":"Hathaway","year":"2024","journal-title":"JAMA Ophthalmol"},{"issue":"1","key":"10.1016\/j.bj.2026.101038_bib60","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s40942-024-00620-x","article-title":"Once-weekly semaglutide doubles the five-year risk of nonarteritic anterior ischemic optic neuropathy in a Danish cohort of 424,152 persons with type 2 diabetes","volume":"10","author":"Grauslund","year":"2024","journal-title":"Int J Retina Vitreous"},{"issue":"6","key":"10.1016\/j.bj.2026.101038_bib61","doi-asserted-by":"crossref","first-page":"3094","DOI":"10.1111\/dom.16316","article-title":"Use of semaglutide and risk of non-arteritic anterior ischemic optic neuropathy: A Danish-Norwegian cohort study","volume":"27","author":"Simonsen","year":"2025","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"10.1016\/j.bj.2026.101038_bib62","doi-asserted-by":"crossref","first-page":"763","DOI":"10.2337\/dc25-2577","article-title":"Glucagon-Like Peptide 1 Receptor Agonists and Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients With Type 2 Diabetes","volume":"49","author":"Noh","year":"2026","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.bj.2026.101038_bib63","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1005064","article-title":"Semaglutide-associated risk of nonarteritic anterior ischemic optic neuropathy in patients with type 2 diabetes: A systematic review and meta-analysis of observational studies","volume":"23","author":"Chrzanowski","year":"2026","journal-title":"PLoS Med"},{"issue":"12","key":"10.1016\/j.bj.2026.101038_bib64","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1016\/j.cgh.2024.10.003","article-title":"Multisociety Clinical Practice Guidance for the Safe Use of Glucagon-like Peptide-1 Receptor Agonists in the Perioperative Period","volume":"23","author":"Kindel","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.bj.2026.101038_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2024.156113","article-title":"Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis","volume":"164","author":"Karakasis","year":"2025","journal-title":"Metabolism"},{"issue":"10531","key":"10.1016\/j.bj.2026.101038_bib66","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0140-6736(25)02105-1","article-title":"Glucagon-like receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits","volume":"407","author":"Nauck","year":"2026","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.bj.2026.101038_bib67","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.afos.2025.05.004","article-title":"Definition and diagnosis of sarcopenia: Asia-Pacific perspectives","volume":"11","author":"Huang","year":"2025","journal-title":"Osteoporosis and Sarcopenia"},{"issue":"5","key":"10.1016\/j.bj.2026.101038_bib68","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.2337\/dc17-2004","article-title":"Impact of Body Weight Loss From Maximum Weight on Fragility Bone Fractures in Japanese Patients With Type 2 Diabetes: The Fukuoka Diabetes Registry","volume":"41","author":"Komorita","year":"2018","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.bj.2026.101038_bib69","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S2213-8587(25)00226-8","article-title":"Once-weekly semaglutide 7.2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial","volume":"13","author":"Wharton","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"10.1016\/j.bj.2026.101038_bib70","doi-asserted-by":"crossref","DOI":"10.1002\/dmrr.70163","article-title":"Not All GLP-1 Receptor Agonists Are Alike: Real-World Evidence of Differential Endocrine and Dermatologic Safety","volume":"42","author":"Lee","year":"2026","journal-title":"Diabetes Metab Res Rev"},{"issue":"9","key":"10.1016\/j.bj.2026.101038_bib71","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1210\/clinem\/dgaf288","article-title":"Preexisting Diabetes and Pregnancy: An Endocrine Society and European Society of Endocrinology Joint Clinical Practice Guideline","volume":"110","author":"Wyckoff","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bj.2026.101038_bib72","unstructured":"FDA Orange Book. 2026."},{"issue":"8","key":"10.1016\/j.bj.2026.101038_bib73","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1111\/dom.14725","article-title":"Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension","volume":"24","author":"Wilding","year":"2022","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"10.1016\/j.bj.2026.101038_bib74","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1001\/jama.2025.24288","article-title":"World Health Organization Guideline on the Use and Indications of Glucagon-Like Peptide-1 Therapies for the Treatment of Obesity in Adults","volume":"335","author":"Celletti","year":"2026","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.bj.2026.101038_bib75","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/s41574-026-01258-5","article-title":"Causes and consequences of discontinuation of GLP1RAs or tirzepatide","volume":"22","author":"Ceriello","year":"2026","journal-title":"Nat Rev Endocrinol"},{"issue":"5","key":"10.1016\/j.bj.2026.101038_bib76","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1001\/jamaneurol.2025.0360","article-title":"Cardioprotective Glucose-Lowering Agents and Dementia Risk: A Systematic Review and Meta-Analysis","volume":"82","author":"Seminer","year":"2025","journal-title":"JAMA Neurol"},{"issue":"10544","key":"10.1016\/j.bj.2026.101038_bib77","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1016\/S0140-6736(26)00459-9","article-title":"Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer\u2019s disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials","volume":"407","author":"Cummings","year":"2026","journal-title":"Lancet"},{"key":"10.1016\/j.bj.2026.101038_bib78","doi-asserted-by":"crossref","DOI":"10.1177\/13872877261458402","article-title":"Semaglutide Showed Limited Improvements in Patients With Alzheimer\u2019s Disease: Revisiting the evoke and evoke+ Clinical Trials","author":"H\u00f6lscher","year":"2026","journal-title":"J Alzheimers Dis"},{"issue":"9","key":"10.1016\/j.bj.2026.101038_bib79","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s00415-025-13301-y","article-title":"Clinical efficacy of GLP-1 receptor agonists in the treatment of Parkinson\u2019s disease: a systematic review and meta-analysis of randomized controlled trials","volume":"272","author":"Zhang","year":"2025","journal-title":"J Neurol"},{"issue":"13","key":"10.1016\/j.bj.2026.101038_bib80","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1056\/NEJMoa2312323","article-title":"Trial of Lixisenatide in Early Parkinson\u2019s Disease","volume":"390","author":"Meissner","year":"2024","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.bj.2026.101038_bib81","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1001\/jamapsychiatry.2024.4789","article-title":"Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial","volume":"82","author":"Hendershot","year":"2025","journal-title":"JAMA Psychiatry"},{"issue":"10540","key":"10.1016\/j.bj.2026.101038_bib82","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(26)00305-3","article-title":"Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial","volume":"407","author":"Klausen","year":"2026","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.bj.2026.101038_bib83","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1001\/jamapsychiatry.2024.3599","article-title":"Repurposing Semaglutide and Liraglutide for Alcohol Use Disorder","volume":"82","author":"L\u00e4hteenvuo","year":"2025","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.bj.2026.101038_bib84","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2025-086886","article-title":"Glucagon-like peptide-1 receptor agonists and risk of substance use disorders among US veterans with type 2 diabetes: cohort study","volume":"392","author":"Cai","year":"2026","journal-title":"BMJ"},{"key":"10.1016\/j.bj.2026.101038_bib85","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2026.14898","article-title":"Once-Weekly Semaglutide in Adults With Daily Cigarette Use","author":"Hendershot","year":"2026","journal-title":"JAMA Netw Open"},{"issue":"8","key":"10.1016\/j.bj.2026.101038_bib86","doi-asserted-by":"crossref","first-page":"4454","DOI":"10.1111\/dom.16489","article-title":"GLP-1 receptor agonists and the risk for cancer: a meta-analysis of randomized controlled trials","volume":"27","author":"Silverii","year":"2025","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"10.1016\/j.bj.2026.101038_bib87","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1001\/jamaoncol.2025.2681","article-title":"GLP-1 Receptor Agonists and Cancer Risk in Adults With Obesity","volume":"11","author":"Dai","year":"2025","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.bj.2026.101038_bib88","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2026.113158","article-title":"Glucagon-like peptide-1 receptor agonists and the risk of obesity-related cancers: a systematic review and meta-analysis","volume":"234","author":"Ateiwi","year":"2026","journal-title":"Diabetes Res Clin Pract"},{"issue":"2","key":"10.1016\/j.bj.2026.101038_bib89","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.58205","article-title":"GLP-1 Receptor Agonists Plus Progestins and Endometrial Cancer Risk in Nonmalignant Uterine Diseases","volume":"9","author":"Yen","year":"2026","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.bj.2026.101038_bib90","article-title":"Repositioning GLP-1 Receptor Agonists in Endometrial Cancer: Molecular Rationale, Preclinical Insights, and Translational Opportunities","author":"Podder","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.bj.2026.101038_bib91","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2026.12133","article-title":"Survival and Recurrence With GLP-1 Receptor Agonists in Breast Cancer","volume":"9","author":"Tatum","year":"2026","journal-title":"JAMA Network Open"},{"key":"10.1016\/j.bj.2026.101038_bib92","article-title":"Risk for Cancer With Glucagon-Like Peptide-1 Receptor Agonists and Dual Agonists: A Systematic Review and Meta-Analysis","author":"Ko","year":"2025","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1016\/j.bj.2026.101038_bib93","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjae160","article-title":"GLP-1 Analog Use is Associated With Improved Disease Course in Inflammatory Bowel Disease: A Report from the Epi-IIRN","volume":"19","author":"Gorelik","year":"2025","journal-title":"J Crohns Colitis"},{"issue":"6","key":"10.1016\/j.bj.2026.101038_bib94","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa2301972","article-title":"Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial","volume":"389","author":"Jastreboff","year":"2023","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.bj.2026.101038_bib95","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1056\/NEJMoa2502081","article-title":"Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity","volume":"393","author":"Garvey","year":"2025","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.bj.2026.101038_bib96","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1056\/NEJMoa2500969","article-title":"Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity","volume":"393","author":"Wharton","year":"2025","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.bj.2026.101038_bib97","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1056\/NEJMoa2511774","article-title":"Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment","volume":"393","author":"Wharton","year":"2025","journal-title":"N Engl J Med"}],"container-title":["Biomedical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2319417026000946?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2319417026000946?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T20:46:18Z","timestamp":1790282778000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2319417026000946"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":97,"alternative-id":["S2319417026000946"],"URL":"https:\/\/doi.org\/10.1016\/j.bj.2026.101038","relation":{},"ISSN":["2319-4170"],"issn-type":[{"value":"2319-4170","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Incretin Revolution: Integrating Incretin-Based Therapies into Clinical Care","name":"articletitle","label":"Article Title"},{"value":"Biomedical Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bj.2026.101038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of Chang Gung University.","name":"copyright","label":"Copyright"}],"article-number":"101038"}}